InnoPharmax Inc. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was TWD 34.65 million compared to TWD 14.69 million a year ago. Net loss was TWD 29.86 million compared to TWD 48.87 million a year ago.

Basic loss per share from continuing operations was TWD 0.33 compared to TWD 0.56 a year ago. Diluted loss per share from continuing operations was TWD 0.33 compared to TWD 0.56 a year ago.